$626 Million Vaccine and Therapeutics Task Order Issued
The U.S. Department of Health and Human Services (HHS) announced a task order worth approximately $628 million has been issued with Emergent BioSolutions to advance manufacturing capabilities and capacity for a potential COVID-19 disease vaccine, as well as therapeutics.
Under the task order, Emergent will deploy its molecule-to-market, contract development, and manufacturing (CDMO) offering, committing manufacturing capacity, valued at approximately $542.7 million, for production of COVID-19 vaccine candidates through 2021.
This award issued on June 1, 2020, secures, on behalf of leading COVID-19 vaccine innovators that are supported by the U.S. government, capacity for drug substance manufacturing at the company’s Baltimore Bayview facility, and for drug product manufacturing at the Baltimore Camden and Rockville locations.
Activities under this task order are in addition to the company’s previously announced collaborations for COVID-19 vaccine candidates with the Janssen Pharmaceutical Companies of Johnson & Johnson, Novavax, and Vaxart that are currently underway.
Syed T. Husain, SVP and CDMO business unit head at Emergent, said in a press statement, “This innovative solution paves the way for pharmaceutical and biotechnology innovators with leading COVID-19 vaccine candidates to have an established U.S. development and manufacturing supply chain.”
“This investment in increased capacity and capabilities will serve the industry’s expanding clinical and commercial pipelines more broadly, ultimately benefiting more patients globally.”
HHS Secretary Alex Azar issued the following statement: “Before a vaccine is even approved, Emergent’s manufacturing capabilities will pave the way for drug companies with vaccine candidates approaching approval to begin turning out doses.”
“Securing more manufacturing capacity here in America for candidates that make it to the final stages of Operation Warp Speed will help get a vaccine to American patients without a day wasted.”
The task order also includes an investment of approximately $85.5 million for the rapid expansion of Emergent’s viral and non-viral CDMO drug product fill/finish capacity at the Baltimore Camden and Rockville facilities.
Emergent’s Baltimore Bayview CIADM facility was established through a public-private partnership with HHS in 2012 and was designed for the rapid manufacturing of large quantities of vaccines and treatments during public health emergencies.
The Baltimore Bayview facility has the capacity to produce tens to hundreds of millions of doses of vaccine on an annual basis, based upon the platform technology being used.
This new task order extends the CIADM collaboration to include viral and non-viral drug product fill/finish capabilities at Emergent’s Rockville and Baltimore Camden facilities.
Emergent BioSolutions is deploying its decades of experience in vaccine and hyperimmune development and manufacturing, as well as its molecule-to-market contract development and manufacturing (CDMO) services to provide comprehensive medical countermeasure solutions in response to the COVID-19 pandemic.
Coronavirus vaccine development news published by Precision Vaccinations.